View Main Condition: Leukemia
Myo Min is a Hematologist Oncology specialist and a Hematologist in Bel Air, Maryland. Dr. Min has been practicing medicine for over 38 years and is rated as an Advanced doctor by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). He is also highly rated in 69 other conditions, according to our data. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Colorectal Cancer. Dr. Min is currently accepting new patients.
Judith Karp is an Oncologist in Baltimore, Maryland. Dr. Karp has been practicing medicine for over 52 years and is rated as an Advanced doctor by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). She is also highly rated in 4 other conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Myelomonocytic Leukemia, and Acute Monoblastic Leukemia (AmoL).
Danielle Shafer is an Oncologist and a Hematologist Oncology doctor in Fairfax, Virginia. Dr. Shafer has been practicing medicine for over 24 years and is rated as an Advanced doctor by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). She is also highly rated in 17 other conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Childhood Acute Myeloid Leukemia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration. Dr. Shafer is currently accepting new patients.
Summary: This randomized phase III trial studies clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as clofarabine, daunorubicin hydrochloride, cytarabine, and decitabine, work in different ways to stop the growth of ca...
Summary: To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D)
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center